The prevalence of life-threatening diseases is increasing rapidly across China, including the number of patients with colorectal cancer, i.e., one of the most commonly occurring diseases which occur in the following two forms:
With growing concerns over such health conditions, there's a burgeoning need for developing better diagnoses & treatments, i.e., demonstrating lucrative prospects for the leading players operating in the entire oncology industry of China.
The China Colorectal Cancer Market is expecting around 3% CAGR during 2022-27. The growth of the market is driven primarily by the rising instances of colorectal cancer among people across China, coupled with the mounting consumer awareness about constant innovations in its treatment & diagnosis.
|Study Period||Historical Data: 2017-20|
|Base Year: 2021|
|Forecast Period: 2022-27|
|Key Companies Profiled||Amgen China, Bristol-Myers Squibb, Bayer AG, Merck KGaA, Roche (china) Co., Ltd., Eli Lilly and Company, Sanofi China, Taiho Pharmaceutical, Novartis AG, Pfizer Inc. etc|
|Unit Denominations||USD Million/Billion|
The leading market players are conducting more and more R&D activities with the massive government support through investments & favorable policies to test & implement different therapies comprising various medications. As a result, several pharmaceutical companies have introduced advanced drugs to address the diverse treatment requirements of colorectal cancer.
Besides, the rapidly growing prevalence of colorectal cancer with high mortality rates is infusing the need for more effective therapeutics. As a result, several existing medications have undergone major R&D innovations with time and demonstrating a growing success rate.
Additionally, the increasing population of colorectal cancer patients in China is generating growth opportunities for the leading players to increase the production of medications at affordable prices, especially for treatments like chemotherapy & immunotherapy, and, as a result, fueling the market growth through 2027.
Key Trend in the China Colorectal Cancer Market
The government of China is investing substantially in the healthcare industry, especially in the oncology sector, to provide better diagnoses and therapies to patients. It, in turn, is also showcasing the active participation of various leading companies in expanding their immuno-oncology portfolios through self-developed assets & partnerships to boost the customer base across the country.
Impact of Covid-19 on the China Colorectal Cancer Market
Across China, being the epicenter of the Covid-19 pandemic, all industries were severely affected and disrupted the nation's economy, and the Colorectal Cancer Market was no exception. Despite immense pressure on the entire healthcare sector in the country, the government immensely supported the industry by increasingly focusing on addressing Covid-19 cases & temporarily subsiding any non-critical health conditions. As a result, it slowed down research & developments associated with the diagnosis & treatment of colorectal cancer.
In addition, most oncologists, though digital platforms, kept track of patients whose conditions were not severe and attended to them only under critical or emergency circumstances. However, patients who required utmost care & treatment were provided the supervision under strict safety protocols amidst the crisis.
Later, with gradual improvements, the government uplifted the restrictions on movement & allowed usual operations across healthcare facilities, along with the recommencement of research & development activities, which enabled the China Colorectal Cancer Market to regain its growth pace.
Based on Treatment:
Surgeries are the most common CRC treatment methods practiced to date. However, chemotherapies, radiotherapies, targeted therapies, immunotherapy, and a combination of these therapies have proved to be highly efficient in improving the overall therapeutic efficacy and extending the survival rate & quality of life for patients. However, when it actually comes to prolonging survival and improving quality of life, targeted therapy combined with chemotherapy significantly enhances progression-free survival & overall survival rates in patients with mCRC and is being increasingly used across China.
Of all treatment types, immunotherapy is the most prominent contributor to the growth of the China Colorectal Cancer Market, principally due to the growing awareness among patients about the minimal chances of any adverse health effects associated with the therapy. Immunotherapy drugs do not exhibit any specificity or toxic side effects but develop resistance in the body to fight cancer. Further, it helps prep the immune system to keep from attacking healthy cells and only targeting cancerous ones. As a result of these benefits, more and more patients prefer this therapy, i.e., augmenting the demand for immunotherapy drugs across China.
On the other hand, chemotherapy, another popular therapy for colorectal cancer practiced widely across China, is anticipated to contribute significantly to the overall market growth during 2022-27. It attributes principally to the increasing patient pool of colorectal cancer and the rising cases of late diagnoses of this health condition. It, in turn, is propelling the demand for adjuvant chemotherapy with fluoropyrimidine & oxaliplatin to reduce recurrence & mortality rates, especially in patients with stage III cancer. The chemotherapy regimens for CRC treatment used in China include FOLFIRI (leucovorin, 5-fluorouracil, irinotecan), mFOLFOX6 (oxaliplatin, 5-fluorouracil, leucovorin), XELOX (capecitabine, oxaliplatin), FOLFOXIRI (leucovorin, 5-fluorouracil, oxaliplatin, irinotecan).
Among various immunotherapy drugs, monoclonal antibodies like Bevacizumab, Cetuximab, & Panitumumab are used frequently in colorectal cancer treatment. These drugs, either alone or combined with radiotherapy or chemotherapy, portray effectiveness & increases the survival chances of patients despite the side effects. Hence, their demand is rapidly surging across China and generating growth prospects for the leading players to introduce more effective monoclonal antibodies for better outcomes while treating patients with colorectal tumors. Bevacizumab & chemotherapy can be used as first-line or second-line treatment for CRC patients with no history of bevacizumab. This combination has portrayed better survival rates than chemotherapy alone. Moreover, Regorafenib is a third-line treatment for CRC patients approved by FDA. It can be used when fluorouracil, oxaliplatin, & irinotecan fail to show effects and has shown great efficacy in prolonging the survival time of Chinese CRC patients.
Key Questions Answered in the Market Research Report:
Frequently Asked Questions
A. The China Colorectal Cancer Market is projected to grow at a CAGR of around 3% during 2022-27.
A. The mounting prevalence of colorectal cancer with high mortality rates is surging the demand for more effective therapeutics and innovations in existing medications and, in turn, driving the China Colorectal Cancer Market.
A. Various pharmaceutical companies are showing greater interest in developing advanced diagnostics & treatment procedures for patients while expanding their immuno-oncology portfolios through self-developed assets & partnerships. This trend projects lucrative prospects for the China Colorectal Cancer Market through 2027.
A. Immunotherapy is anticipated to continue generating remunerative opportunities for the leading players in the China Colorectal Cancer Market over the forecast years.